August 15, 2016

August 2016

Echo Newsletter

Download here (3Mb)      pdf2

bratOsteoporosis in Children - how can you tell and who is at risk

For adults BMD is commonly expressed in T-scores, defined by standard deviations (SD) from the mean peak bone mineral density with T-scores at the lumbar spine or hip of <-2.5 defining osteoporosis .Although this definition is functionally valid for adults, it is not appropriate for children as they have not yet attained peak bone mass. Because the T-score is a measure of bone mineral density compared to early adulthood, its use in children whose BMD and bone mineral content (BMC, in grams) have not yet reached peak will generally yield a low value.


Gynaecologcial Cancers - can GPs make a difference?

In 2008–2012 in Australia, females diagnosed with gynaecological cancer had a 68% chance of surviving for 5 years compared to their counterparts in the general Australian population. > 75% of affected women are diagnosed at an advanced stage because early-stage disease is usually asymptomatic and symptoms of late-stage disease are nonspecific. Advances in surgical and chemotherapeutic strategies have led to improvements in outcome.



17th Nov 2016

listening_to_large_heart_400_clr_13716Dyslipidaemia - how good are statins?

Previous landmark statin trials inform us that statins significantly reduce cardiovascular events, revascularisation procedures and cardiovascular mortality. But wait! Do those risk reduction apply to general practice patients with low or intermediate CV risks?






EyeThe Bionic Eye - how close are we?

Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are two major causes of blindness and low vision in Australia and worldwide. Both these conditions lead to damage of the photoreceptor cells in the retina that are crucial to vision, but leave the optic nerve and visual cortex healthy and intact. The team at UNSW has been researching bionic eye technology since 1997, with the goal of restoring sight to people with retinitis pigmentosa – the leading cause of blindness in younger people – and age-related macular degeneration.

Investigating the patient with haematuria - what’s next?

There is currently no universal agreement about the best way to workup patients with haematuria. The approach is determined by individual patient factors such as age, risk factors for malignancy, renal function, predisposition to calculus disease and pregnancy state of the patient. An important factor in the clinical history is whether that patient is on anticoagulants or not. Clinical presentation also serves to direct the approach to these patients.




Low cost podiatry UniClinic


Can an SGLT2 inhibitor alone or in combination with a DPPIV inhibitor decrease albuminuria and improve glucose control in patients with T2D and moderate chronic kidney disease (CKD3)?

CharcotCharcot foot - can you recognise one when you see one?

Charcot neuro-osteoarthropathy (CNO) of the foot is a serious and potentially limb-threatening lower-extremity complication of diabetes. Swift treatment by offloading the affected limb (usually in a cast) will usually prevent major deformity whilst failure to do so may result in a ‘rockerbottom’ deformity that predisposes to plantar ulceration and frequently results in ulcer-related limb amputation.

Latest Healthpathways

Idiopathic Juvenile arthritis

Paediatric Rheumatology Assessment and Advice

Refugee Services

Refugee Health Assessment

Post FOBT Direct Access Colonoscopy

Dietitics Services in SWS



Free Ophthalmologist Eye Checks for Diabetics in South West Sydney

StemCellsStem Cells - recent advances

The term “stem cell” goes far as back as 1908 when Russian histologist Alexander Maximow developed and introduced a theory of haematopoiesis, a theory upon which our present concept of blood cells' origin and differentiation is based. Basic and clinical research accomplished during the last few years on embryonic, fetal, amniotic, umbilical cord blood, and adult stem cells has constituted a revolution in regenerative medicine and cancer therapies by providing the possibility of generating multiple therapeutically useful cell types.